RecruitingPhase 1NCT07583251

Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

Study For Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

Sponsor

Pravat Mandal

Enrollment

9 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Mild Cognitive Impairment (MCI)

Summary

The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.

Eligibility

Min Age: 55 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Gamma- Glutamylcusteine, a drug called Gamma- Glutamylcysteine, and others for people with mild cognitive impairment (mci). The study is currently recruiting participants at 1 location. People eligible for this study include aged 55 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.